Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.

Peter RossingRajiv AgarwalStefan D AnkerGerasimos FilippatosBertram PittLuis M RuilopeAslam AmodMichel MarreAmer JosephAndrea LageCharlie ScottGeorge L Bakrisnull null

Published in: Diabetes, obesity & metabolism (2021)

This exploratory subgroup analysis suggests that finerenone reduces UACR in patients with or without GLP-1RA use at baseline, and the effects on kidney and CV outcomes are consistent irrespective of GLP-1RA use.

Keyphrases

type diabetes
rheumatoid arthritis
phase iii
clinical trial
ankylosing spondylitis
cardiovascular disease
randomized controlled trial
adipose tissue
interstitial lung disease
insulin resistance
metabolic syndrome
systemic sclerosis
combination therapy
weight loss
replacement therapy
data analysis